Introduction {#S0001}
============

Peripheral artery disease (PAD) affects more than 8 million patients in the United States[@CIT0001],[@CIT0002] and has been associated with morbidity and mortality rates similar to or greater than coronary artery disease (CAD).[@CIT0003]--[@CIT0005] Up to 10% of patients with PAD suffer from chronic limb-threatening ischemia (CLTI).[@CIT0006],[@CIT0007] CLTI is a multilevel disease and is mainly caused by atherosclerosis.[@CIT0008] It has been associated with poor limb salvage (amputation rate up to 50% if left untreated), high mortality[@CIT0009],[@CIT0010] and increased utilization of health-care resources,[@CIT0011]--[@CIT0013] costing more than \$4 billion per year in the United States.[@CIT0002],[@CIT0014],[@CIT0015] The American College of Cardiology/American Heart Association (AHA/ACC) guidelines recommend that revascularization is a reasonable treatment option for CLTI,[@CIT0016] however data regarding best revascularization strategies for CLTI are sparse.[@CIT0017]--[@CIT0019]Figure 1Kaplan--Meier estimates of freedom from major amputation during follow-up.Figure 2Kaplan--Meier estimates of freedom from major amputation/death during follow-up.

Endovascular intervention is a viable treatment approach for CLTI with acceptable hemodynamic improvement and safety profile.[@CIT0015],[@CIT0020] Although endovascular therapy has been increasingly utilized,[@CIT0015],[@CIT0021] the rates of restenosis[@CIT0022]--[@CIT0026] and cardiovascular events are still considerable in CLTI patients.[@CIT0025],[@CIT0026] Variable factors, including heart failure (HF), coronary artery disease (CAD), end-stage renal disease (ESRD) and diabetes, have been associated with an independent risk for higher mortality and worse outcome in patients with CLTI.[@CIT0027]--[@CIT0031] Moreover, several studies have suggested that female patients with symptomatic PAD commonly present at an older age, with more advanced atherosclerosis[@CIT0032],[@CIT0033] and therefore they may have a worse prognosis compared to males.[@CIT0034]--[@CIT0036]

However, it is not yet clear to what extent sex affects the clinical outcomes among CLTI patients who undergo endovascular revascularization.[@CIT0034],[@CIT0037] Identification of such risk factors for worse prognosis could optimize the management of this highly morbid population.[@CIT0031],[@CIT0033],[@CIT0038]-[@CIT0040] Thus, the aim of this study was to determine whether sex is associated with short- and long-term outcomes of endovascular therapy in patients with CLTI. We utilized data from the LIBERTY 360 study, which is a modern, real-world cohort of patients with PAD treated with endovascular approaches.[@CIT0020]

Patients and Methods {#S0002}
====================

Study Design and Patient Enrollment {#S0002-S2001}
-----------------------------------

LIBERTY 360 is a prospective, real-world, multicenter study (ClinicalTrials.gov; identifier: NCT01855412) that examined predictors of clinical and economic outcomes in patients undergoing lower extremity endovascular interventions for symptomatic PAD, with any FDA approved or cleared devices, between 2013 and 2016. Lesions above and below the knee were revascularized, while the target area at the infrapopliteal segment was any lesion in a native vessel located within or extending into 10 cm above the medial epicondyle to the digital arteries. A steering committee, including principal investigators, representatives from the study core laboratories, and the sponsor (Cardiovascular Systems, Inc) developed the study's protocol, while Cardiovascular Systems, Inc was also responsible for oversight of the research process. The protocol for the LIBERTY 360 study was approved by the institutional review board of all the participating sites. The 53 sites which participated in the LIBERTY 360 study are demonstrated in [[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul}. All patients provided written informed consent, and that this trial was conducted in accordance with the Declaration of Helsinki. Details regarding inclusion and exclusion criteria of the LIBERTY 360 study were previously published[@CIT0041] and can also be found at: [<https://clinicaltrials.gov/ct2/show/NCT01855412?cond=NCT01855412&rank=1>]{.ul}.

Renal disease was defined as calculated eGFR \< 60 or kidney damage of at least 3 months; hyperlipidemia was defined as cholesterol levels \> 200mg/dl or LDL \> 100mg/dl or dyslipidemia requiring medication; hypertension was defined as systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg or requiring medication for blood pressure control. For the current study, only patients with CLTI were included and sex-related comparisons were performed (female vs male). A total of 689 patients treated with endovascular procedures for CLTI were ultimately identified. Angiographic data were adjudicated by SynvaCor/Prairie Educational and Research Cooperative (PERC; Springfield, IL, USA). In the analyses of this LIBERTY 360 sub-study core lab data were preferred in order to minimize any potential bias. However, in cases where the core laboratory was not able to assess significant angiographic complications, site reported data were used. Patient demographics and lesion characteristics stratified by sex are summarized in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} respectively.Table 1Baseline Characteristics of ParticipantsCharacteristicsMale (n=437)Female (n=252)P-valueAge, year69.6 ± 10.8 (N=436)70.5 ± 12.0 (N=252)0.306Race American Indian or Alaska Native2 (0.5%)2 (0.8%)0.626 Asian2 (0.5%)0 (0.0%)0.535 Black or African American59 (13.5%)51 (20.2%)0.023 Native Hawaiian or Other Pacific Islander0 (0.0%)1 (0.4%)0.366 White367 (84.0%)194 (77.0%)0.025 Other7 (1.6%)4 (1.6%)1.000BMI29.0 ± 6.0 (N=437)29.4 ± 7.0 (N=252)0.404eGFR60.1 ± 29.0 (N=436)57.9 ± 29.5 (N=252)0.342Smoking history306 (70.0%)133 (52.8%)\<.0001 Current smoker72 (16.5%)44 (17.5%)0.752 Former smoker234 (53.5%)89 (35.3%)\<.0001Diabetes317 (72.5%)169 (67.1%)0.140Hyperlipidemia372 (85.1%)207 (82.1%)0.331Hypertension402 (92.0%)240 (95.2%)0.118Renal disease180 (41.2%)95 (37.7%)0.376Among patients with renal disease, patients being on hemodialysis44 (24.4%)26 (27.4%)0.663Coronary artery disease287 (65.7%)142 (56.3%)0.018Myocardial infarction127 (29.1%)43 (17.1%)0.0005Stroke/TIA60 (13.7%)41 (16.3%)0.373Run-off vessels pre-treatment (Core lab)N=389N=2260.326 349 (12.6%)41 (18.1%)0.076 2152 (39.1%)83 (36.7%)0.606 1137 (35.2%)75 (33.2%)0.660 051 (13.1%)27 (11.9%)0.708Run-off vessels post-treatment (Core lab)N=342N=1920.453 372 (21.1%)49 (25.5%)0.238 2144 (42.1%)72 (37.5%)0.313 1114 (33.3%)67 (34.9%)0.775 012 (3.5%)4 (2.1%)0.436Previous EVT of target limbN=437N=2520.778 No305 (69.8%)164 (65.1%) Yes131 (30.0%)88 (34.9%) Unknown1 (0.2%)0 (0.0%)Previous bypass surgery of target limbN=437N=2520.399 No416 (95.2%)244 (96.8%) Yes20 (4.6%)8 (3.2%) Unknown1 (0.2%)0 (0.0%)Prior stent placed, target limbN=437N=2520.770 No374 (85.6%)216 (85.7%) Yes62 (14.2%)36 (14.3%) Unknown1 (0.2%)0 (0.0%)Previous amputations of target limbN=437N=2520.209 Target limb33 (7.6%)19 (7.5%)1.000 Non-target limb48 (11.0%)19 (7.5%)0.181 Both limbs20 (4.6%)6 (2.4%)0.212 None336 (76.9%)208 (82.5%)0.082If previous amputations, target limbN=53N=250.698 Above knee0 (0.0%)0 (0.0%)-- Below knee/above ankle0 (0.0%)0 (0.0%)-- Toe(s) only50 (94.3%)25 (100.0%)0.547 Foot only4 (7.5%)0 (0.0%)0.300Antiplatelet therapy at discharge405 (92.7%)232 (92.1%)0.767 Aspirin345 (78.9%)204 (81.0%)0.557 Clopidogrel313 (71.6%)196 (77.8%)0.087 Dual284 (65.0%)186 (73.8%)0.018Anti-coagulants at discharge49 (11.2%)29 (11.5%)0.901 Warfarin33 (7.6%)18 (7.1%)0.881 Other16 (3.7%)12 (4.8%)0.549Anti-hyperlipidemic at discharge351 (80.3%)185 (73.4%)0.037Anti-hypertensive at discharge388 (88.8%)229 (90.9%)0.439Hospitalization222 (50.8%)143 (56.7%)0.133Among patients hospitalized, ICU admissionsN=222N=1431.000 No198 (89.2%)127 (88.8%) Yes24 (10.8%)16 (11.2%)Time of admission to discharge, hours44.2 ± 104.2 (N=435)40.1 ± 83.5 (N=252)0.597[^1] Table 2Lesion CharacteristicsCharacteristicsMale (N=596)Female (N=327)P-valueLesion location within the leg (summarized)N=596N=3270.028 ATK Only142 (23.8%)105 (32.1%)0.008 BTK Only375 (62.9%)178 (54.4%)0.014 Unknown1 (0.2%)1 (0.3%)1.0000Lesion location within the legN=596N=3270.025 SFA Only15 (2.5%)14 (4.3%)0.167 SFA to popliteal51 (8.6%)48 (14.7%)0.005 Popliteal only76 (12.8%)43 (13.1%)0.918 ATK and BTK78 (13.1%)43 (13.1%)1.000 SFA to BTK16 (2.7%)13 (4.0%)0.325 Popliteal to BTK62 (10.4%)30 (9.2%)0.646 BTK Only375 (62.9%)178 (54.4%)0.014 Unknown1 (0.2%)1 (0.3%)1.000Mean target lesion length, mm127.4 ± 113.3 (N=559)126.9 ± 117.3 (N=305)0.950Target lesion length (mm)N=559N=3050.929 \<40152 (27.2%)83 (27.2%)1.000 40--99141 (25.2%)80 (26.2%)0.745 ≥100266 (47.6%)142 (46.6%)0.776Mean distal RVD, mm3.2 ± 1.3 (N=574)3.0 ± 1.0 (N=311)0.013Mean preprocedural MLD, mm0.6 ± 0.8 (N=579)0.6 ± 0.8 (N=315)0.856Mean preprocedural stenosis, %83.4 ± 19.6 (N=582)81.8 ± 20.0 (N=316)0.247Chronic total occlusion of the lesion260/582 (44.7%)128/316 (40.5%)0.232TASC lesion typeN=575N=3110.742 A272 (47.3%)144 (46.3%)0.778 B101 (17.6%)62 (19.9%)0.414 C103 (17.9%)58 (18.6%)0.785 D99 (17.2%)47 (15.1%)0.449Predominantly calcified plaque341/553 (61.7%)155/305 (50.8%)0.002PARC stenosisN=582N=3160.654 Mild38 (6.5%)22 (7.0%)0.782 Moderate106 (18.2%)65 (20.6%)0.423 Severe178 (30.6%)101 (32.0%)0.706 Occluded260 (44.7%)128 (40.5%)0.232Target lesion access siteN=648N=3620.242 Femoral597 (92.1%)348 (96.1%)0.016 Popliteal3 (0.5%)2 (0.6%)1.000 Tibial50 (7.7%)18 (5.0%)0.116 Pedal41 (6.3%)17 (4.7%)0.325 Toe0 (0.0%)0 (0.0%)- Brachial1 (0.2%)0 (0.0%)1.000ApproachN=648N=3620.572 Ipsilateral171 (26.4%)85 (23.5%)0.327 Contralateral429 (66.2%)251 (69.3%)0.328 Dual access48 (7.4%)26 (7.2%)1.000Access site position relative to lesionN=648N=3620.614 Anterograde554 (85.5%)316 (87.3%)0.449 Retrograde46 (7.1%)20 (5.5%)0.356 Dual access48 (7.4%)26 (7.2%)1.000Mean postprocedural MLD, mm2.3 ± 1.3 (N=560)2.3 ± 1.1 (N=305)0.967Mean acute MLD gain1.7 ± 1.1 (N=553)1.7 ± 1.1 (N=302)0.931Mean postprocedural stenosis, %35.2 ± 21.6 (N=560)32.0 ± 20.4 (N=306)0.034[^2]

Study Endpoints and Statistical Analysis {#S0002-S2002}
----------------------------------------

Descriptive statistics were used for baseline demographics and lesion characteristics. Categorical variables are presented as absolute and relative frequencies (ie, percentages) and were compared with Monte Carlo approximation of the Fisher\'s exact test. Numeric data are presented as mean ± standard deviation (SD) and compared using ANOVA or a paired *t* test, while discrete data were compared with the Kruskal--Wallis test or Wilcoxon signed-rank test for paired data. Site reported data regarding significant angiographic complications (ie, flow-limiting dissection, perforation, distal embolization, acute vessel closure), procedural and lesion success of core lab identified lesions were used, when core lab was unable to perform angiographic assessment. Primary endpoints were: i) procedural success assessed by the angiographic core laboratory as less than 50% residual stenosis without significant angiographic complications (ie, flow-limiting dissection, perforation, distal embolization, abrupt closure) and ii) incidence of major adverse events (MAE) defined as death within 30 days of the primary procedure, unplanned major amputation of the target limb, and clinically driven target vessel revascularization (CD-TVR) as assessed by the angiographic core laboratory when angiographic images were available. Secondary endpoints were lesion success (\<50% residual stenosis, without significant angiographic complications) target vessel revascularization (TVR), death, major amputation of the target limb, wound healing and the combined outcome of death or major amputation during follow-up. Secondary outcomes also included ankle brachial Index (ABI) and Rutherford class (RC). The ABI and RC were also assessed during follow-up, however as the 3-year follow visit was a phone visit, ABI and RC could be assessed only up to 2 years of follow-up. In addition, Cox regression among males vs females was synthesized for MAE, death, major amputation, and major amputation or death in up to 36 months of follow-up. As no clinically significant differences were identified between male and female baseline demographic, lesion and procedural characteristics, no sensitivity analyses were synthesized. Kaplan-Meier curves for female vs male patients were estimated for primary and secondary outcomes and compared with the Log-rank test. All statistical analyses were conducted by NAMSA (Northwood, OH, USA), and for all tests, p-values \<0.05 were considered statistically significant.

Results {#S0003}
=======

Patients and Lesion Characteristics {#S0003-S2001}
-----------------------------------

A total of 689 patients with CLTI (Female: N=252 vs Male: N=437), with 923 treated lesions (Female: N=327 vs Male: N=596), were included. Detailed patient characteristics are presented in [Table 1](#T0001){ref-type="table"} and [[Supplementary Table 2](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul}. Based on the baseline case report forms, women had lower rates of previous smoking history (Females: 52.8% vs Males: 70.0%; p \<0.001), lower rates of coronary artery disease (CAD) (Females: 56.3% vs Males: 65.7%; p= 0.018), while there were significantly fewer Caucasians in the female group (Females: 77.0% vs Males: 84.0%; p= 0.025). Moreover, women had higher rates of dual-anti-platelet therapy (DAPT) prescription at discharge (Females: 73.8% vs Males: 65.0%; p= 0.018). Women had 126.9±117.3mm mean target lesion length vs men: 127.4±: 113.3mm, without any statistical difference between the two groups (p= 0.950). The women compared to men had more lesions located at the superficial femoral artery (SFA) extending to the popliteal artery (Females: 14.7% vs Males: 8.6%; p= 0.005), while lesions isolated below the knee (BTK) were more commonly observed in men (Females: 54.4% vs Males: 62.9%; p= 0.014). Detailed lesion characteristics are summarized in [Table 2](#T0002){ref-type="table"}.

Procedure Characteristics and Short-Term Outcomes {#S0003-S2002}
-------------------------------------------------

For almost all lesions, balloon angioplasty was the preferred treatment approach (Females: 319/324; 98.5% vs Males: 562/584; 96.2%; p= 0.067), with bailout stenting occurring in 2.8% (N=9/324) of females and in 4.3% (25/584) of males (p=0.280). Important procedural characteristics are provided in [Table 3](#T0003){ref-type="table"}. Overall, significant angiographic complications occurred in 10.5% of all lesions treated (Females: 38/324; 11.7% vs Males: 58/591; 9.8%; p= 0.485). In total, target lesion success, was 78.9% (N=243/307) in the female group vs 78.3% (N=443/566) in male group, without any significant difference between the two groups (p=0.864). In-hospital TVR, MAE and major amputation rates were not statistically different between the two groups, however more in-hospital death occurred among females (Females: 1.2%; N=3/247 vs Males: 0.0%; N=0/422; p= 0.049). The causes of in-hospital death are presented in [[Supplementary Table 3](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul}. Detailed information regarding periprocedural complications and short-term outcomes is presented in [Table 4](#T0004){ref-type="table"} and [[Supplementary Table 4](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul}.Table 3Procedure Characteristics and Target Lesion Device UseCharacteristicsMale (N=437)Female (N=252)P-valueMean procedure time, minutes84.9 ± 47.4 (N=437)77.8 ± 41.3 (N=251)0.049Mean fluoroscopy time, minutes28.1 ± 19.4 (N=434)24.2 ± 15.3 (N=250)0.006Mean Contrast volume, mL166.4 ± 98.3 (N=436)165.4 ± 81.3 (N=250)0.898Inflow vessel disease (\>50% stenosis)151 (34.6%)95 (37.7%)0.410Inflow treatment performed, target limbN=296N=1780.658 No227 (76.7%)133 (74.7%) Yes69 (23.3%)45 (25.3%)Target lesions treated per subject (Core lab)1.4 ± 0.6 (N=436)1.3 ± 0.6 (N=251)0.213Mean number of devices used per subject (atherectomy, balloon, stent)3.5 ± 2.1 (N=437)3.3 ± 2.0 (N=252)0.151Device information available from site (Core lab)N=596N=3270.280 No12 (2.0%)3 (0.9%) Yes584 (98.0%)324 (99.1%)Lesions treated with balloons562/584 (96.2%)319/324 (98.5%)0.067POBA475 (81.3%)256 (79.0%)0.431DCB40 (6.8%)25 (7.7%)0.687Cutting48 (8.2%)36 (11.1%)0.153Focal Force83(14.2%)45 (13.9%)0.921Scoring8 (1.4%)3 (0.9%)0.755Mean maximum nominal balloon diameter, mm3.8 ± 1.4 (N=562)3.8 ± 1.3 (N=319)0.755Mean maximum balloon length, mm139.1 ± 114.1 (N=562)136.7 ± 77.3 (N=319)0.743Bail out stenting25/584 (4.3%)9/324 (2.8%)0.280Lesions treated with atherectomy383/584 (65.6%)219/324 (67.6%)0.558 Diamondback283 (48.5%)152 (46.9%)0.678 Jetstream6 (1.0%)7 (2.2%)0.242 Laser37 (6.3%)18 (5.6%)0.667 Rotablator5 (0.9%)2 (0.6%)1.000 Turbohawk/Silverhawk/HawkOne50 (8.6%)37 (11.4%)0.195 Phoenix9 (1.5%)5 (1.5%)1.000 Bard Crosser3 (0.5%)5 (1.5%)0.142Lesions treated with stent86/584 (14.7%)50/324 (15.4%)0.772DES34 (5.8%)15 (4.6%)0.540BMS53 (9.1%)35 (10.8%)0.414Covered5 (0.9%)1 (0.3%)0.430Mean maximum stent diameter, mm5.1 ± 1.4 (N=86)5.2 ± 1.3 (N=50)0.818Mean maximum stent length, mm81.3 ± 48.5 (N=86)86.3 ± 43.1 (N=50)0.550[^3] Table 4Periprocedural Complications and Short-Term Outcomes (in-Hospital)CharacteristicsMaleFemaleP-valueProcedural success (\<50% residual stenosis, without significant angiographic complications)297/403 (73.7%)179/234 (76.5%)0.451Lesion success (\<50% residual stenosis, without significant angiographic complications)443/566 (78.3%)243/307 (78.9%)0.864Abrupt closure14/594 (2.4%)2/327 (0.6%)0.022Severe angiographic complications58/591 (9.8%)38/324 (11.7%)0.485Severe dissection (Type C-F)20/594 (3.4%)5/327 (1.5%)0.083Perforation9/594 (1.5%)7/327 (2.1%)0.508Distal embolization25/591 (4.2%)24/324 (7.4%)0.106In-hospital MAE3/422 (0.7%)6/247 (2.4%)0.083In-hospital death0/422 (0.0%)3/247 (1.2%)0.049In-hospital major amputation2/422 (0.5%)2/247 (0.8%)0.623In-hospital TVR1/422 (0.2%)1/247 (0.4%)1.000[^4] Table 5Hazard Ratios (HR) and 95% Confidence Intervals of Outcomes During Follow-Up (Male Vs Female)OutcomesHR 95% CIP-value**1-month** MAE1.40 \[0.65, 3.05\]0.391 Death0.57 \[0.12, 2.83\]0.493 Major amputation1.53 \[0.40, 5.75\]0.532 TVR2.68 \[0.77, 9.32\]0.121 Major amputation/death0.95 \[0.35, 2.63\]0.928**6-month** MAE1.23 \[0.84, 1.80\]0.299 Death1.35 \[0.69, 2.66\]0.380 Major amputation1.83 \[0.78, 4.29\]0.162 TVR1.26 \[0.82, 1.93\]0.293 Major amputation/death1.42 \[0.83, 2.42\]0.199**12-month** MAE1.13 \[0.83, 1.54\]0.450 Death1.18 \[0.70, 1.98\]0.546 Major amputation2.13 \[0.98, 4.67\]0.058 TVR1.09 \[0.78, 1.52\]0.627 Major amputation/death1.35 \[0.87, 2.09\]0.175**18-month** MAE 1.10 \[0.82, 1.46\]0.537 Death1.37 \[0.85, 2.22\]0.192 Major amputation2.36 \[1.09, 5.12\]0.030 TVR1.05 \[0.77, 1.43\]0.771 Major amputation/death1.53 \[1.02, 2.30\]0.042**24-month** MAE1.15 \[0.87, 1.53\]0.326 Death1.35 \[0.87, 2.09\]0.178 Major amputation2.02 \[1.00, 4.08\]0.051 TVR1.10 \[0.81, 1.49\]0.527 Major amputation/death1.43 \[0.98, 2.08\]0.060**36-month** MAE1.19 \[0.90, 1.56\]0.224 Death1.24 \[0.85, 1.80\]0.260 Major amputation1.69 \[0.87, 3.26\]0.119 TVR1.13 \[0.84, 1.51\]0.426 Major amputation/death1.29 \[0.93, 1.79\]0.133[^5]

Outcomes in Follow-up {#S0003-S2003}
---------------------

Periprocedural (within 30 days) ABI was improved compared to preprocedural values of each group, with males having a better 30-day ABI overall. ABI values remained higher for males until two years of follow up, however, at 2 years of follow up the change in median ABI from baseline was not statistically different between the two groups. The periprocedural (within 30 days) median Rutherford classification of both groups was similar. No differences in median Rutherford classification between female and male patients were observed during 2 years of follow up. Details about ABI and Rutherford classification (categorical and continuous variables) during follow up are presented in [[Supplementary Table 2](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul}.

Female patients treated for CLTI had a lower risk for major amputation or death during 18-month follow up, compared to males (HR: 1.53; 95% CI: 1.02 - 2.30; p= 0.042). The risk of major amputation at 18-months was lower for the female group (HR: 2.36; 95% CI: 1.09 -5.12; p= 0.030), whereas the 18-month death rates were similar between the groups. At 24 months after the primary procedure although female sex was strongly correlated with less risk for major amputation (HR: 2.02; 95% CI: 1.00 - 4.08; p= 0.051) or the combined outcome of major amputation or death (HR: 1.43; 95% CI: 0.98 - 2.08; p= 0.060), no statistical difference was reached. The risk for major amputation remained similar for females vs males at 36-month follow up as well (HR: 1.69; 95% CI: 0.87-3.26; p= 0.119). The MAE, TVR and mortality risk rates were similar between the two groups and did not change during 36-month follow up.The KM survival curves for major amputation and major amputation or death combined are illustrated in [Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"} respectively. The HRs of the outcomes and the corresponding KM estimates at several follow up time intervals are reported in [Table 5](#T0005){ref-type="table"} and [[Supplementary Table 5](https://www.dovepress.com/get_supplementary_file.php?f=246528.docx)]{.ul} respectively.

Wound Healing Rates {#S0003-S2004}
-------------------

At baseline all patients presented with wound(s) on the target limb. At 6 months of follow-up 20.3% (38/187) female and 29.4% (86/293) male patients were seeing a wound-care specialist for wounds on target limb. Among these patients, the change in seeing a wound care specialist for wound(s) was similar between the two groups (worsened: Females: N=15/187; 8.0% vs Males: N=13/293; 4.4%; p= 0.113; improved: Females: 21.9% vs Males: 16.4%; p= 0.148). The change in seeing a wound care specialist for wound(s) on the target limb remained similar among females and males during 1 year (worsened: Females: N=11/159; 6.9% vs Males: N=10/266; 3.8%; p= 0.168; improved: Females: N=33/159; 20.8% vs Males: N=64/266; 24.1%; p= 0.475) and 2 years (worsened: Females: N=3/127; 2.4% vs Males: N=4/201; 2.0%; p= 1.000; improved: Females: N=32/127 25.2% vs Males: N=54/201; 26.9%; p= 0.797) of follow-up.

Discussion {#S0004}
==========

This study utilized data from the multicenter LIBERTY 360 trial[@CIT0020] to investigate the role of sex in outcomes of CLTI patients undergoing endovascular therapy. In general, there were only a few differences among the groups in terms of baseline characteristics, with fewer female patients being previous smokers, Caucasians or having diagnosed CAD. Our study was based on real-world data and indicated that both female and male patients presented, most commonly, with isolated infrapopliteal disease. This study also demonstrated that females had higher in-hospital all-cause mortality rates compared to men. However, none of the deaths were attributed to the procedure. Separate analyses at several time intervals after the primary procedure provided evidence that although female sex was associated with lower rates of major amputation and major amputation/death combined at 18-month follow-up, the 36-month MAE, TVR and mortality risk rates were similar between the two groups.

Previous studies have investigated several risk factors for the prognosis of endovascular treatment in patients with CLTI.[@CIT0005],[@CIT0042]--[@CIT0045] Although the role of sex has been investigated in CAD and cerebrovascular disease,[@CIT0034],[@CIT0046]-[@CIT0048] sex-related differences in CLTI patients requiring endovascular treatment remains understudied.[@CIT0033],[@CIT0034] Thus, the American Heart Association has called to action studies of women and PAD outcomes.[@CIT0034] CLTI has been associated with high morbidity and mortality, significantly increasing health-care costs.[@CIT0011]--[@CIT0013],[@CIT0049] Moreover, CLTI causes severe physical function restriction with devastating consequences for the patients.[@CIT0050] Thus, as there are no specific guidelines to determine the prognosis of endovascular therapy in CLTI patients, identifying several risk factors related to poor outcomes, could improve management and delay major amputations.[@CIT0049]

In general, it has been observed that female patients often present with more advanced PAD, at an older age compared to men and as such are at higher risk of adverse outcomes.[@CIT0032] A previous retrospective analysis demonstrated that these differences in presentation persisted among patients treated with PTA alone, primary stenting, or atherectomy with/without PTA for symptomatic PAD.[@CIT0051] Additional to differences in presentation, it has been considered that biological sex characteristics might influence the long-term outcomes of revascularization procedures in patients with CLTI.[@CIT0035],[@CIT0036],[@CIT0052]--[@CIT0054] A previous analysis of representative state administrative databases indicated that female sex was associated with higher risk of mortality, especially when women had a history of CAD or cerebrovascular disease.[@CIT0035] Similarly, Ramkumar et al, utilizing data from the Vascular Quality Initiative (VQI) database, suggested that women undergoing endovascular therapy for symptomatic PAD, were at higher risk for reintervention and/or re-occlusion during a median follow-up of 1-year.[@CIT0051] Nonetheless, these studies did not exclusively include patients with CLTI.[@CIT0035],[@CIT0051]

A retrospective study by McCoach et al, investigating the outcome of angioplasty in 97 women and 122 men with CTLI exclusively, demonstrated that women were at higher risk for major adverse cardiovascular events during a median follow-up of 2.2 years, although women had lower prevalence of CAD at baseline.[@CIT0033] In our study (N= 689) no difference was observed in terms of all-cause death during a 3-year follow-up, although the female population of our study had higher prevalence of several comorbidities (eg, CAD, hypertension, diabetes, etc.). Considering that the most common cause of mortality among this high-risk population is cardiovascular death,[@CIT0006] the results of our study were different from the McCoach study. Interestingly, a large multicenter observational study (N=2523) comparing clinical outcomes of endovascular therapy for PAD between women and men showed that female sex was a risk factor for death, MI and major amputation among caludicants.[@CIT0055] However, a sensitivity analysis of this study, including only CLTI cases, failed to show any difference between the female and male group over a median follow-up of 701 days, which was similar to our results.[@CIT0055] Thereby it could be hypothesized that lesion and procedural characteristics rather than biological sex differences affect the prognosis of CLTI patients undergoing endovascular revascularization procedures. However, as data are sparse, more research is warranted in order to identify whether female sex is a risk factor for clinical outcomes of endovascular interventions for CLTI.

Although the late survival rate does not seem to be affected by sex, our study demonstrated a higher incidence of in-hospital death among female patients indicating that sex might play a role in short- rather than long-term outcomes. However, all causes of in-hospital death were not related to the procedure (ie, two death events were attributed to end-stage renal disease and one to amputation due to necrotic toes). ESRD, a high-risk co-morbidity that is a patient-specific variable for early mortality, is independent of sex, as such we believe that female sex is not a risk factor for undergoing endovascular therapy for the treatment of CLTI. In accordance with that, a recent prospective study utilizing data from the Nationwide Inpatient Sample (NIS) database failed to show any association between sex and in-hospital mortality among CLTI patients.[@CIT0056] Miller et al, studying patients with lifestyle limiting claudication, who received endovascular or open surgical repair, demonstrated that women had higher inpatient mortality compared to men, however they suggested that sex might be a predictor for patients with claudication rather CLTI.[@CIT0057] Although several etiologies, including hormonal differences between men and women, have been considered to affect outcomes of revascularization strategies in patients with PAD, the results are conflicting. Therefore, sex-related disparity in CLTI patients undergoing endovascular treatment warrants further research in order to identify whether female sex is a risk factor for late mortality.

Interestingly, our study based on real-world data indicated that female sex might be a protective factor for major amputation at 18-month follow-up. The KM survival estimates for the outcome of major amputation at 18 months (Females: 96.5% vs Males: 91.8%; Log-rank test: p= 0.025) and 24 months (Females: 95.3% vs Males: 91.1%; Log-rank test: p= 0.046) of follow-up were better in females compared to males undergoing endovascular revascularization. Moreover, the KM estimates of freedom from major amputation or death at 18 months of follow-up were also favorable for the female patients, although these results might be driven by the significantly lower amputation rates among females. However, previous studies including either only CLTI patients[@CIT0033] or mixed groups of patients with CLTI/claudication reported similar rates of major amputation between the two groups.[@CIT0033],[@CIT0058] As in our study significantly more men presented with isolated BTK disease, we believe that different lesion characteristics might have affected our results.

Isolated infrapopliteal lesions, being commonly observed among diabetics or patients with ESRD and elderly,[@CIT0059] have been associated with higher incidence of limb loss due to poor initial runoff and severe comorbidities.[@CIT0059] Several studies have indicated that women more commonly present with diffuse femoropopliteal lesions,[@CIT0060] while other investigators have suggested that women with CLTI might have a higher incidence of BTK only disease.[@CIT0061],[@CIT0062] Thus, the data regarding the impact of sex on lesion location and lesion characteristics exhibit high heterogeneity. In our study, most patients had isolated infrapopliteal disease, with men having more isolated lesions located at the infrapopliteal segment than women. The effect of sex on revascularization outcomes in patients with CLTI is yet not clear and most available data are conflicting. We believe that unmeasured patient factors, rather than biological sex characteristics are the cause for the differences observed among women and men with CLTI, undergoing endovascular revascularization. Furthermore, a multivariate assessment of several risk factors will provide a more accurate prediction of outcomes, rather than the assessment of a single characteristic. Further studies are needed to evaluate sex-related variation in prognosis among patients with CLTI.

Limitations {#S0004-S2001}
-----------

The LIBERTY 360 study was a multicenter, core-laboratory adjudicated study with data about patients (ie, patients with CLTI) that were typically excluded from large clinical trials. However, our results should be interpreted in the context of several limitations. First, this is a post hoc analysis of data retrieved from the LIBERTY 360 study, which was an observational nonrandomized study of endovascular therapies, sparing open surgery.[@CIT0020] Second, site and patient participation bias may be resulted due to the requirement of extensive testing. Third, the outcomes might have been affected by the variable devices being used and the different preferred treatment algorithms among the physicians (eg, atherectomy, drug-eluting technology utilization, etc.). Thus, although this study provides important information regarding long-term outcomes (3-year follow-up) of endovascular therapy for CLTI among males vs females, its generalizability might be limited due to the lower drug-eluting technology utilization. However, taking into account the recently raised mortality concerns for DCB technology, this study significantly adds to the literature. Moreover, this study was sponsored by a company promoting atherectomy and as such bias could be attributed to extensive use of orbital atherectomy. Last, the lesion location exhibited high heterogeneity and sensitivity analyses for lesions limited to infrapopliteal or femoropopliteal segment could not be synthesized. Further studies should separately investigate the role of sex in short- and long-term outcomes of femoropopliteal/infrapopliteal revascularizations among patients with CLTI or claudication.

Conclusions {#S0005}
===========

Females exhibited higher in-hospital all-cause mortality among patients undergoing endovascular revascularization, however no death was related to the procedure. At 18-months follow-up, female patients were at lower risk for major amputation and major amputation/death compared to men. Data regarding sex disparity in outcomes of endovascular therapy of patients with CLTI are conflicting. Unmeasured patient factors rather than biological sex characteristics might be the actual cause of these variable results. Further studies should guide the development of treatment algorithms based on multivariate assessment of risk factors for a more accurate prediction of outcomes among female and male patients.
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[^1]: **Abbreviations:** N, number of patients; BMI, body mass index; eGFR, estimated glomerular filtration rate; TIA, transient ischemic attack; EVT, endovascular therapy; ICU, intensive care unit.

[^2]: **Abbreviations:** ATK, above the knee; SFA, superficial femoral; BTK, below the knee; RVD, reference vessel diameter; MLD, minimal lumen diameter; TASC, Trans-Atlantic Inter-Society Consensus Document; PARC, Consensus Definitions from Peripheral Academic Research Consortium; N, number of lesions.

[^3]: **Abbreviations:** POBA, plain balloon angioplasty; DCB, drug-coated balloon; DES, drug-eluting stents; BMS, bare metal stents; N, number of patients.

[^4]: **Abbreviations:** MAE, major adverse event; TVR, target vessel revascularization.

[^5]: **Abbreviations:** MAE, major adverse event; TVR, target vessel revascularization; HR, hazard ratio; CI, confidence interval.
